Effects of oral sodium bicarbonate in patients with CKD.

BACKGROUND AND OBJECTIVES Metabolic acidosis contributes to muscle breakdown in patients with CKD, but whether its treatment improves functional outcomes is unknown. The choice of dose and tolerability of high doses remain unclear. In CKD patients with mild acidosis, this study evaluated the dose-response relationship of alkali with serum bicarbonate, its side effect profile, and its effect on muscle strength. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS In this single-blinded pilot study from March of 2009 to August of 2010, 20 adults with estimated GFR 15-45 ml/min per 1.73 m(2) and serum bicarbonate 20-24 mEq/L were treated during successive 2-week periods with placebo followed by escalating oral NaHCO3 doses (0.3, 0.6, and 1.0 mEq/kg per day). At each visit, handgrip strength and time required to complete 5 and 10 repetitions of a sit-to-stand test were measured. RESULTS Each 0.1 mEq/kg per day increase in dose produced a 0.33 mEq/L (95% confidence interval=0.23-0.43 mEq/L) higher serum bicarbonate. Sit-to-stand time improved after 6 weeks of oral NaHCO3 (23.8±1.4 versus 22.2±1.6 seconds for 10 repetitions, P=0.002), and urinary nitrogen excretion decreased (-0.70 g/g creatinine [95% confidence interval=-1.11 to -0.30] per 0.1 mEq/kg per day higher dose). No statistically significant change was seen in handgrip strength (29.5±9.6 versus 28.4±9.4 kg, P=0.12). Higher NaHCO3 doses were not associated with increased BP or greater edema. CONCLUSIONS NaHCO3 supplementation produces a dose-dependent increase in serum bicarbonate and improves lower extremity muscle strength after a short-term intervention in CKD patients with mild acidosis. Long-term studies are needed to determine if this finding translates into improved functional status.

[1]  T. Hostetter,et al.  Association of serum bicarbonate levels with gait speed and quadriceps strength in older adults. , 2011, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[2]  S. Sheather,et al.  Acid retention accompanies reduced GFR in humans and increases plasma levels of endothelin and aldosterone. , 2011, American journal of physiology. Renal physiology.

[3]  M. Kearney,et al.  The role of IGF-1 resistance in obesity and type 2 diabetes-mellitus-related insulin resistance and vascular disease , 2010, Expert opinion on therapeutic targets.

[4]  R. Garrick Timing of Onset of CKD-Related Metabolic Complications , 2010 .

[5]  M. Raftery,et al.  Bicarbonate supplementation slows progression of CKD and improves nutritional status. , 2009, Journal of the American Society of Nephrology : JASN.

[6]  T. Hostetter,et al.  Serum bicarbonate levels and the progression of kidney disease: a cohort study. , 2009, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[7]  C. Schmid,et al.  A new equation to estimate glomerular filtration rate. , 2009, Annals of internal medicine.

[8]  M. Kearney,et al.  IGF-dependent and IGF-independent actions of IGF-binding protein-1 and -2: implications for metabolic homeostasis , 2009, Trends in Endocrinology & Metabolism.

[9]  M. Rocco,et al.  Physical function in older candidates for renal transplantation: an impaired population. , 2009, Clinical journal of the American Society of Nephrology : CJASN.

[10]  Olivier Moranne,et al.  Timing of onset of CKD-related metabolic complications. , 2009, Journal of the American Society of Nephrology : JASN.

[11]  P. Painter,et al.  Physical functioning in patients with chronic kidney disease. , 2005, Journal of nephrology.

[12]  M. Bossola,et al.  Long-Term Oral Sodium Bicarbonate Supplementation Does Not Improve Serum Albumin Levels in Hemodialysis Patients , 2007, Nephron Clinical Practice.

[13]  National Kidney Foundation K-DOQI: Clinical practice guidelines for bone metabolism and disease in chronic kidney disease , 2007 .

[14]  W. Mitch,et al.  Development of a diagnostic method for detecting increased muscle protein degradation in patients with catabolic conditions. , 2006, Journal of the American Society of Nephrology : JASN.

[15]  W. Mitch,et al.  Chronic kidney disease causes defects in signaling through the insulin receptor substrate/phosphatidylinositol 3-kinase/Akt pathway: implications for muscle atrophy. , 2006, Journal of the American Society of Nephrology : JASN.

[16]  J. Kraut,et al.  Metabolic acidosis of CKD: diagnosis, clinical characteristics, and treatment. , 2005, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[17]  S. Price,et al.  Insulin-like growth factor I: the yin and yang of muscle atrophy. , 2004, Endocrinology.

[18]  G. Eknoyan,et al.  Bone metabolism and disease in chronic kidney disease , 2003 .

[19]  Keith C. Norris,et al.  K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease. , 2003, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[20]  K. Chow,et al.  Oral sodium bicarbonate for the treatment of metabolic acidosis in peritoneal dialysis patients: a randomized placebo-control trial. , 2003, Journal of the American Society of Nephrology : JASN.

[21]  B. Brewer,et al.  Resistance training improves strength and functional measures in patients with end-stage renal disease. , 2002, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[22]  W. Mitch,et al.  Nutrition in CAPD: serum bicarbonate and the ubiquitin-proteasome system in muscle. , 2002, Kidney international.

[23]  C. C. Pillai,et al.  IGFs and IGF-binding proteins in short children with steroid-dependent nephrotic syndrome on chronic glucocorticoids: changes with 1 year exogenous GH. , 2001, European journal of endocrinology.

[24]  P. Painter,et al.  Physical functioning and health-related quality-of-life changes with exercise training in hemodialysis patients. , 2000, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[25]  M. Schambelan,et al.  Anabolic effects of nandrolone decanoate in patients receiving dialysis: a randomized controlled trial. , 1999, JAMA.

[26]  R. Mak Effect of metabolic acidosis on insulin action and secretion in uremia. , 1998, Kidney international.

[27]  J. Hasbargen,et al.  Correction of metabolic acidosis and its effect on albumin in chronic hemodialysis patients. , 1998, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[28]  A. Williams,et al.  High bicarbonate dialysate in haemodialysis patients: effects on acidosis and nutritional status. , 1997, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[29]  J. Walls,et al.  Role of an improvement in acid-base status and nutrition in CAPD patients. , 1997, Kidney international.

[30]  S. Downie,et al.  Correction of acidosis in hemodialysis decreases whole-body protein degradation. , 1997, Journal of the American Society of Nephrology : JASN.

[31]  H. Hulter,et al.  Effect of chronic metabolic acidosis on the growth hormone/IGF-1 endocrine axis: new cause of growth hormone insensitivity in humans. , 1997, Kidney international.

[32]  R. Morris,et al.  Potassium bicarbonate reduces urinary nitrogen excretion in postmenopausal women. , 1997, The Journal of clinical endocrinology and metabolism.

[33]  W. Mitch,et al.  The acidosis of chronic renal failure activates muscle proteolysis in rats by augmenting transcription of genes encoding proteins of the ATP-dependent ubiquitin-proteasome pathway. , 1996, The Journal of clinical investigation.

[34]  J. Vadgama,et al.  Impaired actions of insulin-like growth factor 1 on protein Synthesis and degradation in skeletal muscle of rats with chronic renal failure. Evidence for a postreceptor defect. , 1996, The Journal of clinical investigation.

[35]  D. Fouque,et al.  Impaired metabolic response to recombinant insulin-like growth factor-1 in dialysis patients. , 1995, Kidney international.

[36]  C. Scrimgeour,et al.  Insulin-mediated changes in PD and glucose uptake after correction of acidosis in humans with CRF. , 1995, The American journal of physiology.

[37]  C. Scrimgeour,et al.  Correction of acidosis in humans with CRF decreases protein degradation and amino acid oxidation. , 1993, The American journal of physiology.

[38]  C. Scrimgeour,et al.  Ammonium chloride-induced acidosis increases protein breakdown and amino acid oxidation in humans. , 1992, The American journal of physiology.

[39]  D. Mccarty,et al.  Simple method for measurement of lower extremity muscle strength. , 1985, The American journal of medicine.